AKT1 and cancer: Although the inhibition of PI3K/Akt pathway component appears promising for cancer treatment based on laboratory research, the development of approved medication that directly target members of this signaling pathway has been challenging because of on-target and off-target toxicities associated with direct Akt inhibition (44, 45).